Skip to main content

Health Canada says it has a plan to better communicate with the public about risks from recalled products after an independent review criticized how the recall of Alysena 28 birth-control pills was handled earlier this year.

The federal department asked Ottawa-based Risk Sciences International (RSI) to examine its actions following the recall of the oral contraceptive by its manufacturer, generic drug maker Apotex Inc.

Apotex pulled Alysena 28 from the market when it was discovered one lot contained too little active drug and too much placebo, leaving women who took it vulnerable to becoming pregnant. The lot contained about 50,000 faulty packets, which were sold across Canada.

Story continues below advertisement

In its report released Tuesday, RSI noted that Health Canada wasn't told of the recall until 15 days after Apotex first became aware that incorrect packaging of the product could pose a risk to the public.

RSI concluded that Health Canada followed all of its recall procedures once it was informed by the company that Alysena 28 was being pulled from pharmacy shelves.

Where department staff were lax, it suggested, was in their failure to notify the public as soon as possible – before news of the recall reached Canadians by other means and implied a delay in Health Canada's response.

Health Canada did not notify the media and the public of the recall until April 8 – on the Monday following the Easter long weekend – despite learning of the company's actions four days earlier.

"Health Canada personnel did not act on the opportunity to issue a public communication of the recall of the drug on the afternoon of Friday, April 5, to respond to the social concern associated with unplanned pregnancies," the RSI report said.

"Communications strategists, who are experienced in communicating about socially sensitive issues, were not informed of the recall until Monday, April 8," when an advisory was sent to the media.

Two Canadian class-action lawsuits have been filed against Apotex on behalf of women who became pregnant while taking Alysena 28.

Story continues below advertisement

The law firm that filed one suit in Alberta that's seeking unspecified damages says more than a dozen women have come forward after becoming pregnant while on the pill. In Ontario, a previously filed $800-million suit claims 40 women became pregnant.

RSI pointed out that federal drug regulations don't give clear direction to companies about notification requirements relating to drug recalls, nor do they give Health Canada authority to enforce notification.

The report recommended that laws governing recalls should be strengthened to "include clear statements of the requirements of industry to notify Health Canada within 24 hours of a decision to recall a marketed health product, and provide clear powers to Health Canada to enforce compliance with the requirement."

It also said Health Canada needs to improve its capacity to inform the public about recalls in a more timely fashion.

"Improve awareness of the 24-7 news and information-sharing environment, and revise procedures to enable and support a prompt, inclusive and appropriate response to an emerging drug recall or risk issue," the report advised.

Federal Health Minister Rona Ambrose said her department will explore expanding its recall powers and will work with industry to ensure they provide early notification of any drug recall.

Story continues below advertisement

"The independent review has provided timely and practical recommendations to further strengthen the Canadian drug recall system," Ambrose said in a statement. "We are committed to ensuring Canadians get the information they need, as quickly as possible."

On March 20, Apotex received a complaint of a faulty package, along with a photo, and verified the defect five days later. Then on March 28 – the Thursday before the Easter long weekend – the company decided to recall the lot from which the defective sample had come.

However, it wasn't until Wednesday, April 3, that Apotex sent a notice of recall to wholesalers, distributors and retailers, and it did not notify Health Canada until April 4 – more than two weeks after it was first apprised of the problem.

According to Health Canada's recall policy, Apotex should have notified the federal department's Ontario office verbally or in writing within 24 hours of deciding to pull the affected lot, in other words, on Friday, March 29.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter